Mammary tumor development induces perturbation of liver glucose metabolism with inflammation and fibrosis
Cancer cells rely on glycolysis and lactic fermentation for ATP production, inducing an abnormal glucose uptake in tumors. However, it is largely unknown whether the increased tumor glucose consumption affects overall body glucose homeostasis including perturbation of the liver glucose production pa...
Saved in:
| Published in: | American journal of physiology: endocrinology and metabolism Vol. 328; no. 4; p. E645 |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
01.04.2025
|
| Subjects: | |
| ISSN: | 1522-1555, 1522-1555 |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Cancer cells rely on glycolysis and lactic fermentation for ATP production, inducing an abnormal glucose uptake in tumors. However, it is largely unknown whether the increased tumor glucose consumption affects overall body glucose homeostasis including perturbation of the liver glucose production pathways. The effect of mammary tumor development on the liver metabolism pathway was examined by using a mouse model based on FVB/N wild-type (WT-SD) and FVB/N-Tg(MMTV-PyVT)634Mul/J mice (Tg-SD), who develop spontaneous mammary tumors. Blood and livers were analyzed for metabolic changes, by measuring histological staining, signaling, and insulin sensitivity. Tg-SD mice developed mammary tumors with an average weight of 6 g, and cancer development increased total food intake without impacting body weight gain. Tumor development did not affect blood glycemia and lactate levels but increased insulin and homeostasis model assessment of insulin resistance (HOMA-IR) index (
= 0.06). In the liver, Tg-SD mice with tumors exhibited a decrease in glycogen content and an increase in gluconeogenesis gene expression, as G6pc, Pgc1α, and Foxo1 (
< 0.05), as well as Pepck and Ldha (
< 0.01). Moreover, the phosphorylation of AMPK and AKT was significantly decreased (
< 0.01 and
< 0.05, respectively). Surprisingly, liver fibrosis was markedly increased in Tg mice (
< 0.05) alongside elevated inflammatory gene expression, such as IL1β (
< 0.01) or IL6 (
< 0.05). Here, we found that the development of non-metastatic mammary tumors using the MMTV-PyMT mouse model disrupts liver function through the development of inflammation, fibrosis, and metabolic perturbation, including an increase in glucose production and insulin resistance. Finally, these observations unravel a previously unknown metabolic cross talk between the tumors and the liver.
This work demonstrates that the spontaneous development of non-metastatic mammary tumors triggers hepatic activation of endogenous glucose production pathways, coinciding with the onset of insulin resistance. This finding suggests a significant cross talk between tumors and the liver during tumorigenesis, aiming at enhancing glucose production to meet the elevated energy demands of the tumor. Understanding this interaction could provide insights into metabolic alterations associated with cancer and lead to potential therapeutic targets to inhibit tumor metabolism. |
|---|---|
| AbstractList | Cancer cells rely on glycolysis and lactic fermentation for ATP production, inducing an abnormal glucose uptake in tumors. However, it is largely unknown whether the increased tumor glucose consumption affects overall body glucose homeostasis including perturbation of the liver glucose production pathways. The effect of mammary tumor development on liver metabolism pathway was examined by using a mouse model based on FVB/N wild-type (WT-SD) and FVB/N-Tg(MMTV-PyVT)634Mul/J mice (Tg-SD), who develop spontaneous mammary tumors. Blood and livers were analyzed for metabolic changes, by measuring histological staining, signaling and insulin sensitivity. Tg-SD mice developed mammary tumors with an average weight of 6g, and cancer development increased total food intake without impacting body weight gain. Tumor development did not affect blood glycemia and lactate levels but increased insulin and HOMA-IR index (p=0.06). In the liver, Tg-SD mice with tumors exhibited a decrease in glycogen content, and an increase in gluconeogenesis gene expression, as G6pc, Pgc1α and Foxo1 (p<0.05), as well as Pepck and Ldha (p<0.01). Moreover, the phosphorylation of AMPK and AKT was significantly decreased (respectively (p<0.01 and p<0.05)). Surprisingly, liver fibrosis was markedly increased in Tg mice (p<0.05) alongside elevated inflammatory gene expression, such as IL1β (p<0.01) or IL6 (p<0.05). Here we found that the development of non-metastatic mammary tumors using the MMTV-PyMT mouse model disrupts liver function through the development of inflammation, fibrosis and metabolic perturbation, including an increase in glucose production and insulin resistance. Finally, these observations unravel a previously unknown metabolic crosstalk between the tumors and the liver.Cancer cells rely on glycolysis and lactic fermentation for ATP production, inducing an abnormal glucose uptake in tumors. However, it is largely unknown whether the increased tumor glucose consumption affects overall body glucose homeostasis including perturbation of the liver glucose production pathways. The effect of mammary tumor development on liver metabolism pathway was examined by using a mouse model based on FVB/N wild-type (WT-SD) and FVB/N-Tg(MMTV-PyVT)634Mul/J mice (Tg-SD), who develop spontaneous mammary tumors. Blood and livers were analyzed for metabolic changes, by measuring histological staining, signaling and insulin sensitivity. Tg-SD mice developed mammary tumors with an average weight of 6g, and cancer development increased total food intake without impacting body weight gain. Tumor development did not affect blood glycemia and lactate levels but increased insulin and HOMA-IR index (p=0.06). In the liver, Tg-SD mice with tumors exhibited a decrease in glycogen content, and an increase in gluconeogenesis gene expression, as G6pc, Pgc1α and Foxo1 (p<0.05), as well as Pepck and Ldha (p<0.01). Moreover, the phosphorylation of AMPK and AKT was significantly decreased (respectively (p<0.01 and p<0.05)). Surprisingly, liver fibrosis was markedly increased in Tg mice (p<0.05) alongside elevated inflammatory gene expression, such as IL1β (p<0.01) or IL6 (p<0.05). Here we found that the development of non-metastatic mammary tumors using the MMTV-PyMT mouse model disrupts liver function through the development of inflammation, fibrosis and metabolic perturbation, including an increase in glucose production and insulin resistance. Finally, these observations unravel a previously unknown metabolic crosstalk between the tumors and the liver. Cancer cells rely on glycolysis and lactic fermentation for ATP production, inducing an abnormal glucose uptake in tumors. However, it is largely unknown whether the increased tumor glucose consumption affects overall body glucose homeostasis including perturbation of the liver glucose production pathways. The effect of mammary tumor development on the liver metabolism pathway was examined by using a mouse model based on FVB/N wild-type (WT-SD) and FVB/N-Tg(MMTV-PyVT)634Mul/J mice (Tg-SD), who develop spontaneous mammary tumors. Blood and livers were analyzed for metabolic changes, by measuring histological staining, signaling, and insulin sensitivity. Tg-SD mice developed mammary tumors with an average weight of 6 g, and cancer development increased total food intake without impacting body weight gain. Tumor development did not affect blood glycemia and lactate levels but increased insulin and homeostasis model assessment of insulin resistance (HOMA-IR) index ( = 0.06). In the liver, Tg-SD mice with tumors exhibited a decrease in glycogen content and an increase in gluconeogenesis gene expression, as G6pc, Pgc1α, and Foxo1 ( < 0.05), as well as Pepck and Ldha ( < 0.01). Moreover, the phosphorylation of AMPK and AKT was significantly decreased ( < 0.01 and < 0.05, respectively). Surprisingly, liver fibrosis was markedly increased in Tg mice ( < 0.05) alongside elevated inflammatory gene expression, such as IL1β ( < 0.01) or IL6 ( < 0.05). Here, we found that the development of non-metastatic mammary tumors using the MMTV-PyMT mouse model disrupts liver function through the development of inflammation, fibrosis, and metabolic perturbation, including an increase in glucose production and insulin resistance. Finally, these observations unravel a previously unknown metabolic cross talk between the tumors and the liver. This work demonstrates that the spontaneous development of non-metastatic mammary tumors triggers hepatic activation of endogenous glucose production pathways, coinciding with the onset of insulin resistance. This finding suggests a significant cross talk between tumors and the liver during tumorigenesis, aiming at enhancing glucose production to meet the elevated energy demands of the tumor. Understanding this interaction could provide insights into metabolic alterations associated with cancer and lead to potential therapeutic targets to inhibit tumor metabolism. |
| Author | Bringolf, Anthony Alpy, Fabien Tomasetto, Catherine-Laure Zoll, Joffrey Jaulin, Amélie Crouchet, Emilie Charles, Anne-Laure Baumert, Thomas F Charlot, Anouk Mallard, Joris Duteil, Delphine |
| Author_xml | – sequence: 1 givenname: Anouk orcidid: 0000-0002-4731-3106 surname: Charlot fullname: Charlot, Anouk organization: Biomedicine Research Center of Strasbourg (CRBS), UR 3072 "Mitochondrie, Stress oxydant et Plasticité musculaire,"University of Strasbourg, Strasbourg, France – sequence: 2 givenname: Anthony surname: Bringolf fullname: Bringolf, Anthony organization: Biomedicine Research Center of Strasbourg (CRBS), UR 3072 "Mitochondrie, Stress oxydant et Plasticité musculaire,"University of Strasbourg, Strasbourg, France – sequence: 3 givenname: Joris orcidid: 0009-0009-0890-3136 surname: Mallard fullname: Mallard, Joris organization: Institute of Cancerology Strasbourg Europe (ICANS), Strasbourg, France – sequence: 4 givenname: Amélie surname: Jaulin fullname: Jaulin, Amélie organization: IGBMC UMR 7104-UMR-S 1258, CNRS, Inserm, Université de Strasbourg, Illkirch, France – sequence: 5 givenname: Emilie surname: Crouchet fullname: Crouchet, Emilie organization: Institute for Translational Medicine and Liver Disease, UMR-S1110, Inserm, University of Strasbourg, Strasbourg, France – sequence: 6 givenname: Anne-Laure orcidid: 0000-0003-3557-2642 surname: Charles fullname: Charles, Anne-Laure organization: Biomedicine Research Center of Strasbourg (CRBS), UR 3072 "Mitochondrie, Stress oxydant et Plasticité musculaire,"University of Strasbourg, Strasbourg, France – sequence: 7 givenname: Delphine surname: Duteil fullname: Duteil, Delphine organization: IGBMC UMR 7104-UMR-S 1258, CNRS, Inserm, Université de Strasbourg, Illkirch, France – sequence: 8 givenname: Fabien surname: Alpy fullname: Alpy, Fabien organization: IGBMC UMR 7104-UMR-S 1258, CNRS, Inserm, Université de Strasbourg, Illkirch, France – sequence: 9 givenname: Catherine-Laure surname: Tomasetto fullname: Tomasetto, Catherine-Laure organization: IGBMC UMR 7104-UMR-S 1258, CNRS, Inserm, Université de Strasbourg, Illkirch, France – sequence: 10 givenname: Thomas F surname: Baumert fullname: Baumert, Thomas F organization: Service d'Hépato-gastroentérologie, University Hospital of Strasbourg, Strasbourg, France – sequence: 11 givenname: Joffrey orcidid: 0009-0006-0090-1484 surname: Zoll fullname: Zoll, Joffrey organization: Faculty of Medicine, University of Strasbourg, Strasbourg, France |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40106327$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkMlOwzAYhC0Eogu8AAfkI5cWL3HiHFHFJhVxgXPkxH_AlZdgO0W8PS0UidOMNN_MYWbo2AcPCF1QsqRUsGu1GcDrsCSkqOWSEVYcoekuYAsqhDj-5ydoltKGEFKJgp2iSUEoKTmrpsg8KedU_MJ5dCFiDVuwYXDgMzZejx0kPEDMY2xVNsHj0GNrthDxmx27kAA7yKoN1iSHP01-37V6u5_8oZXXuDdtDMmkM3TSK5vg_KBz9Hp3-7J6WKyf7x9XN-tFx3mRF0qVopaCU9DQlqrTqqippoKC7BUILrRshapk1UvaS5Cq1oKXlEjdcZBaszm6-t0dYvgYIeXGmdSBtcpDGFPDaVWzQoi63KGXB3RsHehmiGb_RfN3D_sGq-Ztmg |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1152/ajpendo.00498.2024 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine Anatomy & Physiology |
| EISSN | 1522-1555 |
| ExternalDocumentID | 40106327 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: Alsace contre le cancer |
| GroupedDBID | --- 23M 39C 4.4 5GY 6J9 AAFWJ ABJNI ACPRK ADBBV AENEX AFRAH ALMA_UNASSIGNED_HOLDINGS BAWUL BKKCC BKOMP BTFSW CGR CUY CVF E3Z EBS ECM EIF EMOBN F5P H13 ITBOX KQ8 NPM OK1 P2P P6G PQQKQ RAP RHI RPL RPRKH TR2 WH7 WOQ XSW YSK 7X8 |
| ID | FETCH-LOGICAL-c334t-aa6598531edeb6acda491d151e8fae535d8b5a787f81f8e8a9d536108dc3e8dd2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 0 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001487062500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1522-1555 |
| IngestDate | Fri Jul 11 11:22:55 EDT 2025 Fri May 16 02:44:49 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | breast cancer liver gluconeogenesis insulin resistance Warburg effect |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c334t-aa6598531edeb6acda491d151e8fae535d8b5a787f81f8e8a9d536108dc3e8dd2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0003-3557-2642 0009-0006-0090-1484 0009-0009-0890-3136 0000-0002-4731-3106 |
| OpenAccessLink | https://hal.science/hal-05213245 |
| PMID | 40106327 |
| PQID | 3179245596 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_3179245596 pubmed_primary_40106327 |
| PublicationCentury | 2000 |
| PublicationDate | 2025-04-01 |
| PublicationDateYYYYMMDD | 2025-04-01 |
| PublicationDate_xml | – month: 04 year: 2025 text: 2025-04-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | American journal of physiology: endocrinology and metabolism |
| PublicationTitleAlternate | Am J Physiol Endocrinol Metab |
| PublicationYear | 2025 |
| SSID | ssj0007542 |
| Score | 2.470038 |
| Snippet | Cancer cells rely on glycolysis and lactic fermentation for ATP production, inducing an abnormal glucose uptake in tumors. However, it is largely unknown... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | E645 |
| SubjectTerms | Animals Female Gluconeogenesis Glucose - metabolism Inflammation - metabolism Inflammation - pathology Insulin Resistance Liver - metabolism Liver - pathology Liver Cirrhosis - etiology Liver Cirrhosis - metabolism Liver Cirrhosis - pathology Mammary Neoplasms, Experimental - metabolism Mammary Neoplasms, Experimental - pathology Mice Mice, Transgenic |
| Title | Mammary tumor development induces perturbation of liver glucose metabolism with inflammation and fibrosis |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/40106327 https://www.proquest.com/docview/3179245596 |
| Volume | 328 |
| WOSCitedRecordID | wos001487062500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8QwEA6-EC--1sf6IoJ4q0ubpklPIqJ4cBcPKntb0k4CK9t23e4K_ntnsl32JAheempKSSaZ75v5MsPYlYxskkEqAgWUZkQaFBgQMghDMEiJVJz4Ys_vz6rX0_1--tIE3OpGVrk4E_1BDVVOMfIO-jmkCoh_k9vxZ0Bdoyi72rTQWGXrAqEMWbXqL6uFU3dXXy8VCRf6Tbm4NCOjjvmgFrPVDSFkUnjRjfffIKZ3NY87__3JXbbdgEx-N7eKPbZiy33WuiuRYBff_Jp72aePp--zzW6TXW-xYdf4m2x8OiuqCYelnogjc0cbqPnYTtBHZX45eeX4iGQdvNG988JO0aZGw7rgFN_FUW5En_RvmxK4Q3Je1cP6gL09PrzePwVNK4YgFyKeBsYkMkXPHlqwWWJyMHEaAqIFq52xUkjQmTS4-Z0OnbbapCAFIjMNubAaIDpka2VV2mPGDWTSIW5QNs1jAcpQibJM5do5MBmoNrtczO0ATZ3yF6a01aweLGe3zY7mCzQYz2tyDGLitiJSJ38Yfcq2Iuri6_U3Z2zd4Ua352wj_5oO68mFtyF89l66P2ev1IY |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Mammary+tumor+development+induces+perturbation+of+liver+glucose+metabolism+with+inflammation+and+fibrosis&rft.jtitle=American+journal+of+physiology%3A+endocrinology+and+metabolism&rft.au=Charlot%2C+Anouk&rft.au=Bringolf%2C+Anthony&rft.au=Mallard%2C+Joris&rft.au=Jaulin%2C+Am%C3%A9lie&rft.date=2025-04-01&rft.eissn=1522-1555&rft.volume=328&rft.issue=4&rft.spage=E645&rft_id=info:doi/10.1152%2Fajpendo.00498.2024&rft_id=info%3Apmid%2F40106327&rft_id=info%3Apmid%2F40106327&rft.externalDocID=40106327 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1522-1555&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1522-1555&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1522-1555&client=summon |